Dr. Cohen on Fixed-Duration Therapy in CLL

Dr. Cohen on Fixed-Duration Therapy in CLL

Fixed-Duration Therapy for Relapsed CLLПодробнее

Fixed-Duration Therapy for Relapsed CLL

The future of fixed-duration therapy in CLLПодробнее

The future of fixed-duration therapy in CLL

Dr. Cohen on Chemoimmunotherapy in CLLПодробнее

Dr. Cohen on Chemoimmunotherapy in CLL

Fixed-duration treatment strategies for frontline and relapsed CLLПодробнее

Fixed-duration treatment strategies for frontline and relapsed CLL

CLL14: feasibility of fixed-duration frontline therapy in CLLПодробнее

CLL14: feasibility of fixed-duration frontline therapy in CLL

Fixed duration treatment strategies in CLLПодробнее

Fixed duration treatment strategies in CLL

Factors to consider when selecting between continuous and fixed-duration therapy in CLLПодробнее

Factors to consider when selecting between continuous and fixed-duration therapy in CLL

Fixed-duration vs continuous therapy in CLLПодробнее

Fixed-duration vs continuous therapy in CLL

Dr. Cohen on the ELEVATE-TN Trial in CLLПодробнее

Dr. Cohen on the ELEVATE-TN Trial in CLL

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLLПодробнее

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Fixed Duration vs. Continuous Duration Therapy in CLLПодробнее

Fixed Duration vs. Continuous Duration Therapy in CLL

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLLПодробнее

Dr. Al-Sawaf on Fixed-Duration Versus Continuous Treatment in CLL

Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbiditiesПодробнее

Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclaxПодробнее

Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax

CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLLПодробнее

CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL

Comparing continuous and fixed duration therapy in CLLПодробнее

Comparing continuous and fixed duration therapy in CLL

Choosing between continuous versus fixed-duration therapy in CLLПодробнее

Choosing between continuous versus fixed-duration therapy in CLL

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLLПодробнее

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

Understanding patient perspectives in CLL treatmentПодробнее

Understanding patient perspectives in CLL treatment